Traders should consider this a positive catalyst given the combination of commercial launch and 7-year market exclusivity in a high-unmet-need pediatric population. The exclusivity reduces near-term competitive risk and supports premium pricing and reimbursement. Monitor sales ramp in upcoming quarters as a key indicator of uptake.
ASND drugs
ASND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 7 $220.48entry
- T+1 · 7mo ago +5.77%α +3.23% · $233.20
- T+5 · 7mo ago +13.32%α +7.99% · $249.84
- T+20 · 7mo ago +3.73%α −6.05% · $228.71
- T+60 · 5mo ago +24.50%α +11.23% · $274.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly treatment for children with achondroplasia, has been granted orphan drug exclusivity by the FDA and is now commercially available in the United States. The exclusivity extends through February 27, 2033, providing market protection for this first-in-class therapy.
Key Facts
- YUVIWEL (navepegritide) received orphan drug exclusivity from the FDA
- YUVIWEL is now commercially available in the U.S.
- It is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia
- Orphan drug exclusivity runs through February 27, 2033
- The drug provides continuous systemic exposure to CNP over the weekly dosing interval
Financial Impact
Significant long-term revenue potential due to market exclusivity and first-mover advantage in a rare disease indication
Risk Factors
- Market acceptance and reimbursement challenges
- Dependence on third-party manufacturers and supply chain
- Potential safety or efficacy findings post-launch
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-144463 |
| Document: 0001193125-26-144463-index-headers.html | 0001193125-26-144463 |
| Document: 0001193125-26-144463-index.html | 0001193125-26-144463 |
| Document: 0001193125-26-144463.txt | 0001193125-26-144463 |
Track record
41 reports on ASND
13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
- Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
- Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
- Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers